Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2016 Oct;14(10):929-41. doi: 10.1080/14787210.2016.1222272. Epub 2016 Aug 17.

Emerging infection and sepsis biomarkers: will they change current therapies?

Author information

1
a Department of Pediatrics, Division of Critical Care Medicine , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.
2
b Critical Care Medicine , Cincinnati Children's Hospital Medical Center , Cincinnati , OH , USA.

Abstract

INTRODUCTION:

Sepsis is a heterogeneous syndrome characterized by both immune hyperactivity and relative immune suppression. Biomarkers have the potential to improve recognition and management of sepsis through three main applications: diagnosis, monitoring response to treatment, and stratifying patients based on prognosis or underlying biological response.

AREAS COVERED:

This review focuses on specific examples of well-studied, evidence-supported biomarkers, and discusses their role in clinical practice with special attention to antibiotic stewardship and cost-effectiveness. Biomarkers were selected based on availability of robust prospective trials and meta-analyses which supported their role as emerging tools to improve the clinical management of sepsis. Expert commentary: Great strides have been made in candidate sepsis biomarker discovery and testing, with the biomarkers in this review showing promise. Yet sepsis remains a dynamic illness with a great degree of biological heterogeneity - heterogeneity which may be further resolved by recently discovered gene expression-based endotypes in septic shock.

KEYWORDS:

IL-27; PERSEVERE; Sepsis; bioscore; cfDNA; endotype; immune system; nCD64; presepsin; procalcitonin

PMID:
27533847
PMCID:
PMC5087989
DOI:
10.1080/14787210.2016.1222272
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center